Autoimmune disorders, rheumatoid arthritis, systemic inflammation, and immune dysregulation
307 artigos
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Researchers used blood biomarkers and machine learning to predict which expensive RA treatments work best for individual patients.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
Study reveals how inflammation blocks growth hormone production and tests whether etanercept can restore healthy levels in women with RA.
Researchers modified red blood cells to teach the immune system tolerance, potentially ending need for harsh immunosuppressive drugs.
Revolutionary precision immunotherapies use AI and cellular engineering to target lupus at its source, offering hope for durable remission.
HSCT therapy achieves drug-free remission in patients with treatment-resistant autoimmune conditions like lupus and rheumatoid arthritis.
Revolutionary cancer treatment successfully treats treatment-resistant autoimmune disease, offering hope for severe cases.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
New antigen-specific tolerance approach could treat multiple sclerosis and related diseases without broad immunosuppression.
